Alex Hillenbrand

The FDA has not approved the sNDA for tasimelteon in jet lag disorder in its current form, citing positive efficacy but limited real-world applicability.

Quarter 4 2025 showed robust advancements in the nephrology field, including FDA news, trial updates, and featured content.

An age-based observational study in glomerular disease suggests different rates of disease progression and remission in young adults compared to adult and pediatric patients.

The FDA grants priority review of Vera Therapeutics’s Biologics License Application for the B-cell modulating, atacicept, in IgAN.

Retrospective data suggest serum creatinine trajectories might predict 28-day mortality in acute kidney injury on chronic kidney disease.

A cross-sectional study in CKD suggests patients undergoing hemodialysis have increased social frailty and depression compared to transplant recipients.

A qualitative descriptive study of pediatric kidney transplant recipients and caregivers highlights a need for standardized educational materials and treatment information.

New research in patients with end-stage kidney disease suggests an association between neighborhood advantage and access to transplants and waitlists.

In December 2025, intervention strategies, dialysis modalities, and kidney transplantation data provided insight to improve renal care for clinicians.

C3G treatment advances in 2025 with FDA approvals of iptacopan and pegcetacoplan, offering disease-modifying options

FDA clears first human umbilical cord–derived sheet device, Theracor, for wound Care

The FDA grants breakthrough therapy designation for ulizacaltamine for the treatment of essential tremor.

IgA nephropathy advanced in 2025 with FDA approvals, positive phase 3 trials, and growing disease-modifying therapies

In 2025, FDA approvals, pivotal trials, and emerging therapies shifted nephrology care toward precision and mechanism-driven kidney medicine.

A multinational survey suggests even slowly progressing C3G and IC-MPGN substantially affect patients, caregivers, and healthcare systems.

Findings from a retrospective observational cohort study indicate podometrics may inform a less invasive treatment approach in IgA nephropathy (IgAN).

A multi-state cross-sectional analysis linked chronic kidney disease with increased COVID-19 hospitalizations, indicating more severe disease outcomes

A cross-sectional study compares renal transplantation with dialysis, highlighting an improved sleep quality in end-stage renal disease.

A cross-sectional study indicates a link between urinary levels of measured metals and metalloids and the stages of cardiovascular-kidney-metabolic syndrome.

A retrospective observational cohort study identifies an association between patients undergoing peritoneal dialysis and their physical activity level.

A retrospective cohort study developed and validated a predictive model for IgA nephropathy, using routinely available variables.

A meta-epidemiologic study highlights barriers to inclusion of older adults undergoing maintenance dialysis in randomized controlled trials.

A review of 32 years of global data on FSGS highlights increased prevalence, with a limitation of biopsy variation and regional practices.

Cross-sectional analysis from NHANES shows patients with advanced cardiovascular-kidney-metabolic syndrome are at an increased sarcopenia risk.

FDA approves zoliflodacin (Nuzolvence) for uncomplicated gonorrhea, offering a new oral treatment amid rising antibiotic resistance.

Weight-adjusted waist index outperforms obesity indices for cardiovascular disease prediction in cardiovascular-kidney-metabolic syndrome

Findings comparing kidney-after-liver to simultaneous transplant highlight similarities in allograft survival outcomes, but notable eGFR differences.

VTL-308 post-hoc analysis shows corticosteroids may decrease AKI risk in severe alcohol-associated hepatitis, but don’t affect recovery.

In women with CKD, there are no general survival advantages compared to the male patient population.

A retrospective cohort in finerenone showed nearly 40% proteinuria reduction at 8 months and stable eGFR in patients with IgA nephropathy.